Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.
Clinical role
Notification-only triage and worklist prioritization in parallel with standard of care; full images remain the diagnostic source.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Not a diagnostic device; inadequate field of view is excluded; the FDA testing input range was 0.5-2.5 mm axial slices; the preview has no finding marking and full PACS images must be reviewed.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Filtered DICOM contrast-enhanced CT images including the brain; adults or transitional adults aged 18 and older; 0.5-2.5 mm axial slices.
Who uses it?Intended users: Hospital networks and appropriately trained medical specialists.
What does the software produce?Output: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only when a suspected brain aneurysm at least 3.0 mm is flagged.
What is its most important limitation?Key limitation: Not a diagnostic device; inadequate field of view is excluded; the FDA testing input range was 0.5-2.5 mm axial slices; the preview has no finding marking and full PACS images must be reviewed.
Clinical takeaway. Clinical role: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.
Evidence takeaway. Evidence from the reviewed source record: FDA retrospective, blinded, multicenter pivotal study: 544 cases from six U.S. clinical sites, with ground truth from three senior board-certified radiologists and test data distinct from training. Primary sensitivity was 87.8% (95% CI 83.1-91.6) and specificity 91.6% (87.9-94.5). Secondary results included NPV 98.9%, PPV 47.6%, PLR 10.5, NLR 0.13, and mean time-to-notification 44.8 seconds (95% CI 41.4-48.2; n=241) versus 252 seconds for the predicate; the timing measure was calculated for true-positive cases.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.
A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only when a suspected brain aneurysm at least 3.0 mm is flagged.
Not a diagnostic device; inadequate field of view is excluded; the FDA testing input range was 0.5-2.5 mm axial slices; the preview has no finding marking and full PACS images must be reviewed.
FDA retrospective, blinded, multicenter pivotal study: 544 cases from six U.S. clinical sites, with ground truth from three senior board-certified radiologists and test data distinct from training. Primary sensitivity was 87.8% (95% CI 83.1-91.6) and specificity 91.6% (87.9-94.5). Secondary results included NPV 98.9%, PPV 47.6%, PLR 10.5, NLR 0.13, and mean time-to-notification 44.8 seconds (95% CI 41.4-48.2; n=241) versus 252 seconds for the predicate; the timing measure was calculated for true-positive cases.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA retrospective, blinded, multicenter pivotal study: 544 cases from six U.S. clinical sites, with ground truth from three senior board-certified radiologists and test data distinct from training. Primary sensitivity was 87.8% (95% CI 83.1-91.6) and specificity 91.6% (87.9-94.5). Secondary results included NPV 98.9%, PPV 47.6%, PLR 10.5, NLR 0.13, and mean time-to-notification 44.8 seconds (95% CI 41.4-48.2; n=241) versus 252 seconds for the predicate; the timing measure was calculated for true-positive cases.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
BriefCase-Triage Brain Aneurysm regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested version2
Samplen=544
Sites6
IndependenceIndependence not established
K251195
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251195. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Filtered DICOM contrast-enhanced CT images including the brain; adults or transitional adults aged 18 and older; 0.5-2.5 mm axial slices.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Linux-based cloud server receives filtered DICOM through an image communication platform and sends results to a desktop feed/non-diagnostic viewer for review of the original PACS images; exact current interfaces and versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only when a suspected brain aneurysm at least 3.0 mm is flagged.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A pop-up notification and compressed, low-quality, grayscale, unannotated preview labeled not for diagnostic use and for prioritization only when a suspected brain aneurysm at least 3.0 mm is flagged.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Linux-based cloud server receives filtered DICOM through an image communication platform and sends results to a desktop feed/non-diagnostic viewer for review of the original PACS images; exact current interfaces and versions are not established.
Aidoc's current public Security & Privacy page says its security work is led by a CISO and security team, that it has adopted the NIST Cybersecurity Framework, and that its platform runs on AWS and Azure using EDR, encryption, SIEM and CSPM tooling. The page's list of standards and certifications did not load as readable text, so no certification is stated here.
Vendor-wide
Checked 2026-10-25
Vendor-wide marketing statement, not an independent attestation. It does not establish certificate scope or expiry, the controls of this exact release, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Aidoc's security page states that its platform runs on AWS and Azure and that customer data protection is achieved with the use of EDR, encryption, SIEM, CSPM and other technologies.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Aidoc's platform generally and does not scope these capabilities to any specific product release; exact-release scope is not established. The page lists technology categories in use; it states no uptime, alerting or response-time SLAs.
ACR AI Central provides an exact-submission model card for BriefCase-Triage; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor product page, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K251195 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.